Metrics cut 1
- Performance Chemical 2 commercial production delayed to Q3 FY27 (November) from prior September timeline; revenue now expected from Q1 FY28
Event Participants
Executives
2
Parnerkar, Sanjay (Chief Financial Officer); Sikchi, Siddharth (Managing Director & Promoter)
Analysts
8
Abhijit Akella (Kotak Institutional Equities); Ankur Periwal (Axis Capital); Manish (Individual Investor); Nilesh Ghuge (HDFC Securities); Rohit Nagraj (360 ONE Capital); Sanjesh Jain (ICICI Securities); Saurabh Banik (Bevis Consultants); Shreyans Gathani (SG Securities)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹264 crores | Highest ever; +7% QoQ, +10% YoY, driven by HALS scale-up across higher-grade mix |
| Standalone Revenue | ₹203 crores | +5% QoQ on improved realizations across all products; -6% YoY on supply-side volume headwinds (~2-week supplier shutdown) |
| Consolidated EBITDA | ₹96 crores (37% margin) | Operating leverage from HALS consolidation driving margin expansion |
| Consolidated PAT | ₹73 crores (28% margin) | Steady profitability as HALS monetization phase begins |
| Standalone EBITDA | ₹87 crores (43% margin) | +5% QoQ vs adjusted Q4 FY26 EBITDA of ₹83 crores |
| Standalone PAT | ₹73 crores (36% margin) | +37% QoQ vs adjusted Q4 FY26 PAT of ₹53 crores (one-off expenses adjusted) |
| HALS Share of Sales | 22% of consolidated revenue | Exports now ~50% of HALS sales vs entirely domestic in first year; CFCL operationally self-sustaining |
| Top 4 Legacy Products Share | 60% | De-risked concentration; down from 85% in Q4 FY23 |
| HALS Volume (Q1) | ~1,000 metric tons | Annualized run-rate supports FY27 target of 3,000 MT |
| HALS Realization | ~₹550/kg | Improved from ~₹440/kg on grade mix shift (770 → 622); HALS 770 mix reduced from 50% to 35% |
| Capex in CFCL (Q1) | ₹100 crores | Cumulative investment in subsidiary now ~₹850 crores |
| Standalone Export Mix | 65% domestic / 35% export | Steady export profile for legacy portfolio |
Geographic & Segment Commentary
Performance Chemicals (Legacy): Revenue moderated 6% YoY due to supply-side headwinds — the primary Indian raw material supplier shut down for ~2 weeks on propylene non-availability. Demand remains steady; sequential revenue improved 5% on better realizations, with volumes expected to normalize from Q2 as availability returns, though price volatility persists.
HALS (via subsidiary Clean Fino Chem): Continued scale-up driving operating leverage and sustainable profit improvement; now 22% of sales with exports contributing ~50%. CFCL achieved operational self-sustainability milestone, transitioning from investment to monetization phase. Grade mix shifting toward higher-value products (622 grades), with 30-40% lower grade / 60-70% higher grade capacity split.
HQ/Catechol (Performance Chemical 1): Plant stabilization largely completed; customer approvals received and commercial supply ramp-up underway, with revenue expected from Aug-Sep 2026 as operational efficiencies improve.
Pharma & FMCG: Consolidated sales mix stands at Performance Chemicals 83%, Pharma 10%, and FMCG 7%, reflecting balanced end-market exposure.
Company-Specific & Strategic Commentary
Geneus Chem Collaboration: Strategic partnership with Swiss technology company for advanced NOR HALS chemistry — patented, differentiated products for agricultural film applications in harsh environments (dominated by BASF globally). Tech transfer with co-branded marketing, geography-defined to avoid overlap; ~₹25 crores capex for plant starting Q3 FY27. Revenue target of ₹300-350 crores over 3-4 years, plus additional offtake for Clean Science's own 2020 intermediate.
Kemin Five-Year Contract: Definitive agreement with global food/feed ingredient buyer (existing 10-year customer) for BHA, BHT, TBHQ across all global locations; offtake expected to increase 20-40% starting within 2-3 months. Additional capacity investments underway; secures assured volumes and preempts competitors.
Product De-risking: Top four legacy products reduced from 85% of sales (Q4 FY23) to 60% this quarter, diversifying revenue base while HALS scales toward 30-35% of total revenue in FY27.
Netherlands Subsidiary: Operational from mid-September 2026 to cater to European demand; aligns with India-Europe trade agreements.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| HALS Revenue (FY27) | ₹250-300 crores (30-35% of total revenue) | Comfortable to achieve; ~1,000 MT in Q1 annualizes to 3,000+ MT run-rate |
| HALS Volume (FY27) | ~3,000 metric tons | Management confirmed comfort with target |
| Geneus Chem Revenue | ₹300-350 crores over 3-4 years | Cumulative target including committed volumes from partner; peak year ~₹100 crores |
| HQ/Catechol Revenue | From Aug-Sep 2026 | Customer approvals received; gradual ramp-up as production scales |
| Performance Chemical 2 | Commercial production Q3 FY27 (Nov); revenue from Q1 FY28 | November-March will be stabilization phase; delayed from earlier timeline due to labor issues |
| HALS EBITDA Margins | Gradual improvement | Driven by higher-grade mix and operational efficiencies as plant matures |
Risks & Constraints
| Risk | Context |
|---|---|
| Raw Material Price Volatility | Middle East geopolitical tensions keep crude-linked RM prices volatile; management notes pricing pressure persists and full pass-through is not possible under long-term contracts. Standalone margins could face pressure in near term. |
| Supply Chain Disruption | Indian supplier shutdown (~2 weeks in Q1) and shipping vessel non-availability impacted exports; reduced revenue potential. Management planning safety stocks but cannot fully control external factors. |
| Pricing Power Limitations | Long-term contracts with customers (e.g., Kemin) restrict ability to fully pass on RM cost increases; only partial price pass-through achieved in some segments. |
| Foreign Competition | Chinese competitors in MEHQ value chain and established HALS players (BASF, SABO, Rianlon, UniteChem) remain competitive threats, though current pricing environment remains favorable. |
Q&A Highlights
HALS Ramp & Product Mix
- Question: What drove the HALS growth — volume or pricing mix, and what portion is beyond 770 grades? (Sanjesh Jain)
- Answer: Product mix improved from 770 to 622 grades; average realizations moved from ~₹440 to ~₹550/kg. Volumes were ~1,000 tons in Q1. HALS 770 contribution reduced from 50% to 35% of volumes, improving gross margins at subsidiary level. (Siddharth Sikchi, Sanjay Parnerkar)
Geneus Chem Collaboration Structure
- Question: Is Clean Science acting as contract manufacturer with tech belonging to the Swiss partner, and what is the revenue potential? (Sanjesh Jain; Ankur Periwal)
- Answer: The collaboration involves technology transfer with co-branding and joint marketing; geographies are clearly divided to avoid overlap. Revenue target of ₹300-350 crores over 3-4 years is only for Clean Science's direct sales — partner's mark-up is over and above. No transfer fees or royalties; exclusively capex of ~₹25 crores. These are patented NOR HALS products, a completely new market segment currently dominated by BASF, which also opens cross-selling opportunities for existing HALS grades. (Siddharth Sikchi)
Kemin Agreement Details
- Question: Is this a new customer, and what commercial benefits are being extended? Will it require incremental capacity? (Ankur Periwal; Sanjesh Jain)
- Answer: Kemin is an existing customer of 10 years; this increases wallet share across BHA, BHT, and TBHQ for all their global locations. The contract provides supply security with no volume-based discounts; five-year definitive commitment preempts competitors. Offtake expected to increase 20-40% starting within 2-3 months, requiring additional capacity investments already initiated. (Siddharth Sikchi; Sanjay Parnerkar)
Legacy Business Supply Impact
- Question: Was the YoY decline in legacy business solely due to raw material availability? (Sanjesh Jain)
- Answer: Yes, the primary Indian raw material supplier shut down for ~2 weeks due to propylene non-availability, impacting production. Demand remains absolutely steady; volumes should normalize from Q2, though raw material pricing and shipping vessel availability remain concerns across the industry. (Siddharth Sikchi)
Gross Margin Sustainability
- Question: Are the improved gross margins sustainable, or were they aided by low-cost inventory? (Sanjesh Jain)
- Answer: Margins of 43-45% are sustainable; there was no advantage from cheap raw materials. Improvements come from moving to higher-grade products and improved operational efficiencies. However, raw material prices have risen with Middle East tensions, and price increases going forward remain uncertain. (Siddharth Sikchi)
HALS Competitive Landscape
- Question: Who are the core competitors in domestic and export markets for HALS? (Saurabh Banik)
- Answer: Two major European competitors — BASF and SABO — and two Chinese players, Rianlon and Suqian (UniteChem). Customer approvals for Clean Science grades are now complete, enabling commercial shipments and export ramp-up. (Siddharth Sikchi)
Supply Chain Outlook for Upcoming Quarters
- Question: Has the supply situation improved in July, and can we expect smoother operations? (Rohit Nagraj; Abhijit Akella)
- Answer: Supply availability has improved — companies have built safety stocks; however, crude oil-linked raw material price volatility continues to be a profitability concern. Management has planned supply chain buffers to avoid facility stoppages, but acknowledged external factors remain beyond full control. (Siddharth Sikchi)
Performance Chemical 2 Timeline
- Question: Is Performance Chemical 2 on track for September commercial production? (Shreyans Gathani)
- Answer: Delayed due to labor issues in recent months; now expected to start in November (Q3 FY27). November-March will be stabilization phase, with major revenue expected from Q1 FY28. (Siddharth Sikchi)
Key Takeaway
Clean Science delivered its highest-ever consolidated sales of ₹264 crores in Q1 FY27 (+7% QoQ, +10% YoY), with HALS scaling to 22% of revenue and CFCL reaching operational self-sustainability after ~₹850 crores cumulative investment. Standalone revenue grew 5% QoQ to ₹203 crores despite ~2 weeks of production loss from supplier shutdowns and shipping constraints, with EBITDA and PAT margins at 43% and 36% respectively. Strategically, management signed two significant agreements: a collaboration with Swiss firm Geneus Chem for patented NOR HALS chemistry targeting ₹300-350 crores over 3-4 years, and a five-year supply contract with Kemin for food-grade antioxidants expected to lift offtake 20-40%. FY27 guidance includes HALS revenue of ₹250-300 crores (30-35% of total) and 3,000 MT volumes, with Performance Chemical 2 commercializing in Q3 and HQ/catechol ramping from August. Key watch points include crude-linked raw material price volatility, partial pass-through limitations under long-term contracts, and geopolitical supply chain disruptions that could pressure near-term profitability despite improving volume trajectory.